Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q4 EPS of ($0.40), $0.03 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $870 thousand versus the consensus estimate of $552.72 thousand.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.